These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 24573551

  • 1. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Apr 15; 20(8):2029-34. PubMed ID: 24573551
    [Abstract] [Full Text] [Related]

  • 2. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R.
    Oncologist; 2014 Oct 15; 19(10):e5-11. PubMed ID: 25170012
    [Abstract] [Full Text] [Related]

  • 3. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 15; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 15; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 5. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ.
    Arch Pathol Lab Med; 2012 Oct 15; 136(10):1201-4. PubMed ID: 23020724
    [Abstract] [Full Text] [Related]

  • 6. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May 15; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 7. Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
    Kazandjian D, Blumenthal GM, Luo L, He K, Fran I, Lemery S, Pazdur R.
    Oncologist; 2016 Aug 15; 21(8):974-80. PubMed ID: 27328934
    [Abstract] [Full Text] [Related]

  • 8. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.
    Lung Cancer; 2015 Feb 15; 87(2):89-95. PubMed ID: 25576294
    [Abstract] [Full Text] [Related]

  • 9. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH.
    Expert Rev Anticancer Ther; 2012 Feb 15; 12(2):151-62. PubMed ID: 22316363
    [Abstract] [Full Text] [Related]

  • 10. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 15; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 11. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 15; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 12. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul 15; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 13. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Jul 15; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 14. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 15. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.
    J Clin Oncol; 2016 Mar 01; 34(7):661-8. PubMed ID: 26598747
    [Abstract] [Full Text] [Related]

  • 16. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A, Wood K, Salgia R.
    Expert Opin Drug Saf; 2015 Mar 01; 14(3):485-93. PubMed ID: 25659177
    [Abstract] [Full Text] [Related]

  • 17. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
    Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.
    Lancet Oncol; 2011 Oct 01; 12(11):1004-12. PubMed ID: 21933749
    [Abstract] [Full Text] [Related]

  • 18. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 19. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J.
    Lung Cancer; 2016 Aug 01; 98():9-14. PubMed ID: 27393500
    [Abstract] [Full Text] [Related]

  • 20. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators.
    N Engl J Med; 2014 Dec 04; 371(23):2167-77. PubMed ID: 25470694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.